Last updated: 4 September 2024 at 5:09pm EST

Neal Walker Net Worth




The estimated Net Worth of Neal Walker is at least 8.67 百万$ dollars as of 1 September 2024. Neal Walker owns over 9,466 units of Aclaris Therapeutics Inc stock worth over 1,611,430$ and over the last 10 years he sold ACRS stock worth over 3,911,193$. In addition, he makes 3,150,020$ as President、 Chief Executive Officer、 Co-Founder、 Director at Aclaris Therapeutics Inc.

Neal Walker ACRS stock SEC Form 4 insiders trading

Neal has made over 30 trades of the Aclaris Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 9,466 units of ACRS stock worth 11,170$ on 1 September 2024.

The largest trade he's ever made was exercising 156,679 units of Aclaris Therapeutics Inc stock on 1 March 2023 worth over 184,881$. On average, Neal trades about 22,010 units every 70 days since 2014. As of 1 September 2024 he still owns at least 1,365,619 units of Aclaris Therapeutics Inc stock.

You can see the complete history of Neal Walker stock trades at the bottom of the page.





Neal Walker biography

Dr. Neal Walker serves as President, Chief Executive Officer, Co-Founder, Director of the Company. Dr. Walker co-founded our company and has served as President and Chief Executive Officer and a member of our Board since our inception in July 2012. Dr. Walker co-founded NeXeption, LLC in 2012 and NeXeption II, LLC in 2013. Between 2011 and 2012, Dr. Walker served as a consultant to a number of pharmaceutical companies. Dr. Walker co-founded and served as President and Chief Executive Officer and a member of the board of directors of Vicept Therapeutics, Inc., a dermatology-focused specialty pharmaceutical company, from 2009 until its acquisition by Allergan, Inc. in 2011. Previously, Dr. Walker co-founded and led a number of life science companies, including Octagon Research Solutions, Inc., a software and services provider to biopharmaceutical companies (acquired by Accenture plc), Trigenesis Therapeutics, Inc., a specialty dermatology company, where he served as Chief Medical Officer (acquired by Dr. Reddy’s Laboratories Inc.), and Cutix Inc., a commercial dermatology company. He began his pharmaceutical industry career at Johnson and Johnson, Inc. Dr. Walker is a director of Alderya Therapeutics, Inc., a publicly held biotechnology company, as well as several private biotechnology companies. Dr. Walker received his M.B.A. degree from The Wharton School, University of Pennsylvania, his Doctor of Osteopathic Medicine degree from the Philadelphia College of Osteopathic Medicine and a B.A. degree in Biology from Lehigh University. Dr. Walker’s experience as a board-certified dermatologist and the founder of our company and other pharmaceutical companies, his background in clinical and product development in dermatology and other fields, and his knowledge of the pharmaceutical industry contributed to the conclusion of our Board that he should serve as a director of our company.

What is the salary of Neal Walker?

As the President、 Chief Executive Officer、 Co-Founder、 Director of Aclaris Therapeutics Inc, the total compensation of Neal Walker at Aclaris Therapeutics Inc is 3,150,020$. There are no executives at Aclaris Therapeutics Inc getting paid more.



How old is Neal Walker?

Neal Walker is 50, he's been the President、 Chief Executive Officer、 Co-Founder、 Director of Aclaris Therapeutics Inc since 2012. There are 13 older and 1 younger executives at Aclaris Therapeutics Inc. The oldest executive at Aclaris Therapeutics Inc is Maxine Gowen, 62, who is the Independent Director.

What's Neal Walker's mailing address?

Neal's mailing address filed with the SEC is C/O ACLARIS THERAPEUTICS, INC., 701 LEE ROAD, SUITE 103, WAYNE, PA, 19087.

Insiders trading at Aclaris Therapeutics Inc

Over the last 9 years, insiders at Aclaris Therapeutics Inc have traded over 101,608,525$ worth of Aclaris Therapeutics Inc stock and bought 10,163,038 units worth 66,383,599$ . The most active insiders traders include Braden Michael LeonardCapital Management, Llc Kol...Llc Fmr. On average, Aclaris Therapeutics Inc executives and independent directors trade stock every 17 days with the average trade being worth of 111,818$. The most recent stock trade was executed by Kevin Balthaser on 1 September 2024, trading 1,000 units of ACRS stock currently worth 1,180$.



What does Aclaris Therapeutics Inc do?

aclaris therapeutics, inc. is a dermatologist-led biopharmaceutical company committed to identifying, developing and commercializing innovative therapies to address significant unmet needs in dermatology, both medical and aesthetic, and immunology. aclaris is focused on market segments with no fda-approved medications or where treatment gaps exist. aclaris was founded by dermatologists and is led by a team with extensive experience in developing and commercializing dermatologic treatments.



What does Aclaris Therapeutics Inc's logo look like?

Aclaris Therapeutics Inc logo

Complete history of Neal Walker stock trades at Aclaris Therapeutics Inc、Aldeyra Therapeutics Inc

日付
#
会社
インサイダー
取引
取引
株式 1株当たりの株価 合計金額 その後の株式数 ソース
1 Sep 2024 Neal Walker
INTERIM PRESIDENT AND CEO
オプション行使 9,466 1.18$ 11,170$
1 Sep 2024
1,365,619
9 Aug 2024 Neal Walker
INTERIM PRESIDENT AND CEO
オプション行使 43,548 0.72$ 31,355$
9 Aug 2024
1,356,153
1 Aug 2024 Neal Walker
INTERIM PRESIDENT AND CEO
オプション行使 9,467 1.32$ 12,496$
1 Aug 2024
1,315,327
1 Jul 2024 Neal Walker
INTERIM PRESIDENT AND CEO
オプション行使 9,467 1.15$ 10,887$
1 Jul 2024
1,308,582
1 Jun 2024 Neal Walker
INTERIM PRESIDENT AND CEO
オプション行使 9,466 1.03$ 9,750$
1 Jun 2024
1,301,837
1 May 2024 Neal Walker
INTERIM PRESIDENT AND CEO
オプション行使 9,467 1.26$ 11,928$
1 May 2024
1,295,155
1 Apr 2024 Neal Walker
INTERIM PRESIDENT AND CEO
オプション行使 9,467 1.26$ 11,928$
1 Apr 2024
1,288,912
1 Mar 2024 Neal Walker
INTERIM PRESIDENT AND CEO
オプション行使 9,466 1.24$ 11,738$
1 Mar 2024
1,282,668
1 Mar 2023 Neal Walker
INTERIM PRESIDENT AND CEO
オプション行使 156,679 12.24$ 1,917,751$
1 Mar 2023
1,303,442
1 Feb 2023 Neal Walker
INTERIM PRESIDENT AND CEO
販売 30,000 16.66$ 499,800$
1 Feb 2023
1,175,763
3 Jan 2023 Neal Walker
INTERIM PRESIDENT AND CEO
販売 40,000 15.11$ 604,400$
3 Jan 2023
1,205,763
21 Apr 2022 Neal Walker
INTERIM PRESIDENT AND CEO
販売 70,000 15.15$ 1,060,500$
21 Apr 2022
1,245,763
11 Mar 2022 Neal Walker
INTERIM PRESIDENT AND CEO
販売 56,303 15.91$ 895,781$
11 Mar 2022
1,315,763
1 Mar 2022 Neal Walker
INTERIM PRESIDENT AND CEO
オプション行使 132,679 14.94$ 1,982,224$
1 Mar 2022
1,372,066
9 Feb 2022 Neal Walker
INTERIM PRESIDENT AND CEO
販売 3,595 12.66$ 45,513$
9 Feb 2022
1,239,387
1 Feb 2022 Neal Walker
INTERIM PRESIDENT AND CEO
オプション行使 10,800 11.58$ 125,064$
1 Feb 2022
1,242,982
1 Jun 2021 Neal Walker
INTERIM PRESIDENT AND CEO
オプション行使 73,015 23.64$ 1,726,075$
1 Jun 2021
1,265,442
22 Apr 2021 Neal Walker
INTERIM PRESIDENT AND CEO
販売 30,000 26.84$ 805,200$
22 Apr 2021
1,192,427
1 Mar 2021 Neal Walker
INTERIM PRESIDENT AND CEO
オプション行使 114,403 24.06$ 2,752,536$
1 Mar 2021
1,230,409
1 Feb 2021 Neal Walker
INTERIM PRESIDENT AND CEO
オプション行使 10,800 21.35$ 230,580$
1 Feb 2021
1,159,114
15 Dec 2020 Neal Walker
INTERIM PRESIDENT AND CEO
オプション行使 3,034 4.59$ 13,926$
15 Dec 2020
1,149,185
1 Sep 2020 Neal Walker
INTERIM PRESIDENT AND CEO
オプション行使 83,092 2.33$ 193,604$
1 Sep 2020
1,170,023
1 Jun 2020 Neal Walker
INTERIM PRESIDENT AND CEO
オプション行使 73,014 1.32$ 96,378$
1 Jun 2020
1,107,907
2 Mar 2020 Neal Walker
INTERIM PRESIDENT AND CEO
オプション行使 148,714 1.26$ 187,380$
2 Mar 2020
1,049,994
3 Feb 2020 Neal Walker
INTERIM PRESIDENT AND CEO
オプション行使 10,800 1.28$ 13,824$
3 Feb 2020
932,578
18 Dec 2019 Neal Walker
INTERIM PRESIDENT AND CEO
オプション行使 2,925 1.81$ 5,294$
18 Dec 2019
922,521
16 Dec 2019 Neal Walker
INTERIM PRESIDENT AND CEO
オプション行使 3,033 1.80$ 5,459$
16 Dec 2019
920,378
5 Apr 2018 Neal Walker
INTERIM PRESIDENT AND CEO
購入する 10,000 16.75$ 167,500$
5 Apr 2018
897,184
22 Aug 2023 Neal Walker
オプション行使 9,604 0.55$ 5,282$
22 Aug 2023
15,854
7 May 2014 Neal Walker
購入する 6,250 8.00$ 50,000$
7 May 2014
6,250


Aclaris Therapeutics Inc executives and stock owners

Aclaris Therapeutics Inc executives and other stock owners filed with the SEC include: